Publications

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer

Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, et al., for the RMC-6236-001 Investigators

N Engl J Med

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer

Kim D, Sim NS, Woo S, Kim MH, Lee CK, Hong SS, Kim SH, Hwang HK, Kang CM, Lee WJ, Jo JH, Chung T, Hwang S, Kang B, Kim JS, Kwon CI, Kim S, Chon HJ, Kim CG, Park YN, Choi HJ

Clinical and Molecular Hepatology 32(2), 721–736

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

Park W, Kasi A, Spira AI, Paz-Ares Rodríguez L, Herzberg BO, Pelster MS, et al.

N Engl J Med

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, … Park W, …

Nature Medicine 31(2), 466–477

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K, Jang GH, … Park W, …

Cancer Cell 42(9), 1614–1629